Syros Pharmaceuticals To Present New Data On SY-1425, Its First-in-Class Potent And Selective RARa Agonist, At The ASH Annual Meeting

Syros Pharmaceuticals (NASDAQ: SYRS) today announced that new data on its lead candidate, SY-1425, a selective retinoic acid receptor alpha (RARa) agonist currently in Phase 2 clinical development in genomically defined subsets of patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), will be highlighted in two presentations at the 58 th American Society of Hematology (ASH) Annual Meeting and Exhibition taking place December 3-6, 2016, in San Diego.

The new preclinical data will demonstrate that SY-1425 produces a biologic response in in vitro models of AML with high levels of RARA gene expression similar to that seen in models of acute promyelocytic leukemia (APL), while having little effect on AML cells with low levels of RARA gene expression. APL is a form of AML with a distinct genetic alteration in the RARA gene. SY-1425 is approved in Japan for the treatment of APL, with a well-established efficacy and safety profile. The consistent biological responses suggest that SY-1425 may provide a clinical benefit for subsets of AML patients whose tumors are driven by high levels of RARA as it does in APL patients. In both diseases, RARa is a key oncogenic driver directly targeted by SY-1425.

The presentations also will detail the identification of pharmacodynamic markers to measure the biological activity of SY-1425 in an ongoing Phase 2 clinical trial in order to provide an early indicator that the drug is affecting the targeted biology in AML and MDS patients. Lastly, the preclinical data will show that SY-1425 increases the anti-tumor activity of chemotherapy and hypomethylating agents, supporting the potential development of SY-1425 as a combination therapy with these standard-of-care treatments for AML and MDS patients.

Details on the presentations are as follow:

Date & Time: Saturday, December 3, from 5:30 - 7:30 p.m. PSTPresentation Title: SY1425 (tamibarotene) Induces Profound Transcriptional Changes in AML Tumors with High Retinoic Acid Receptor AlphaSession: 602. Disordered Gene Expression in Hematologic Malignancy, including Disordered Epigenetic Regulation: Poster IPresenter: Christopher Fiore, Ph.D., Scientist, Syros PharmaceuticalsAbstract Number: 1523Location: San Diego Convention Center, Hall GH